In April, a relatively difficult month for patent owners, the PTAB cancelled 524 (86.33%) instituted claims across 43 IPR and PGR Final Written Decisions, including decisions following remand from the Federal Circuit. Only 69 (11.37%) instituted claims survived review, and patent owners conceded 14 (2.31%) instituted claims through motions to amend or disclaimer in cases reaching a final decision. For comparison, the cumulative average cancellation rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 72%.
On a per-case basis, no instituted or substitute claims survived in 34 (79.07%) decisions, all instituted claims survived in 3 (6.98%) decisions, and a mixed outcome occurred in 6 (13.95%) decisions. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision.
Through April 30, 2023, the PTAB has cumulatively granted 600 (16.57%) proposed substitute claims in motions to amend while denying 3,020 (83.43%) proposed substitute claims in IPRs.
The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through April 30, 2023, broken down by technology center, is as follows:
The cumulative number of Final Written Decisions through April 30, 2023, separated by technology center, is as follows:
Additional cumulative statistics on the Board's IPR, CBM, and PGR decisions, updated through April 30, 2023, are available here on the At the PTAB blog.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
